Abstract
The search for effective cancer therapies is one of the foremost priorities of modern-day research. In recent times, enormous strides have been made in the understanding of the molecular events that underlie cancer progression and in the development of promising therapies against relevant molecular targets. The molecular signalling pathways that modulate tumourigenesis, especially those involved in cell migration and adhesion are logical foci for molecular intervention. Angiogenesis is a validated target from which combination approaches are now being entertained, and agents against new and known targets are under development. Further advances are needed to use these agents to their best advantage and to demonstrate proof of concept of the target. To that end, new technologies are being developed and applied to patient trials. The local microenvironment and the tumour-host interface are dynamic areas that are understudied as therapeutic directions. Stromal therapy, focused to the paracrine interactions at the microenvironmental level is an important new direction.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Liotta, L. A., and Kohn, E. C., 2001, The microenvironment of the tumour-host interface. Nature, 411:375–379.
Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G., 1991, Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64:327–336.
Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A., 1993, Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol, 9:541–573.
Longhurst, C. M., and Jennings, L. K., 1998, Integrin-mediated signal transduction. Cell Mol Life Sci, 54:514–526.
Pece, S., and Gutkind, J. S., 2000, Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J Biol Chem, 275:41227–41233.
Hubbard, A. K., and Rothlein, R., 2000, Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med, 28:1379–1386.
Anand-Apte, B., and Zetter, B., 1997, Signaling mechanisms in growth factor-stimulated cell motility. Stem Cells, 15:259–267.
Wells, A., 1999, EGF receptor. Int J Biochem Cell Biol, 31:637–643.
Friedl, P., and Brocker, E. B., 2000, The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci, 57:41–64.
Petruzzelli, L., Herrera, R., and Rosen, O. M., 1984, Insulin receptor is an insulin-dependent tyrosine protein kinase: copurification of insulin-binding activity and protein kinase activity to homogeneity from human placenta. Proc Natl Acad Sci U S A, 81:3327–3331.
Downward, J., Waterfield, M. D., and Parker, P. J., 1985, Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem, 260:14538–14546.
Claesson-Welsh, L., 1994, Signal transduction by the PDGF receptors. Prog Growth Factor Res, 5:37–54.
Pawson, T., 2002, Regulation and targets of receptor tyrosine kinases. Eur J Cancer, 38Suppl 5: S3–10.
Mendelsohn, J. and Baselga, J., 2003, Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol, 21:2787–2799.
Baselga, J., 2002, Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 7Suppl 4:2–8.
Ciardiello, F., and Tortora, G., 2001, A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7:2958–2970.
Fay, F. S., Gilbert, S. H., and Brundage, R. A., 1995, Calcium signalling during chemotaxis. Ciba Found Symp, 188:121–135; discussion 136–140.
Huang, J. B., Kindzelskii, A. L., Clark, A. J., and Petty, H. R., 2004, Identification of channels promoting calcium spikes and waves in HT1080 tumor cells: their apparent roles in cell motility and invasion. Cancer Res, 64:2482–2489.
Lee, J., Ishihara, A., Oxford, G., Johnson, B., and Jacobson, K., 1999, Regulation of cell movement is mediated by stretch-activated calcium channels. Nature, 400:382–386.
Munevar, S., Wang, Y. L., and Dembo, M., 2001, Distinct roles of frontal and rear cell-substrate adhesions in fibroblast migration. Mol Biol Cell, 12:3947–3954.
Webb, D. J., Donais, K., Whitmore, L. A., Thomas, S. M., Turner, C. E., Parsons, J. T., and Horwitz, A. F., 2004, FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol, 6:154–161.
Chan, A. Y., Raft, S., Bailly, M., Wyckoff, J. B., Segall, J. E., and Condeelis, J. S., 1998, EGF stimulates an increase in actin nucleation and filament number at the leading edge of the lamellipod in mammary adenocarcinoma cells. J Cell Sci, 111 (Pt 2):199–211.
Azuma, T., Witke, W., Stossel, T. P., Hartwig, J. H., and Kwiatkowski, D. J., 1998, Gelsolin is a downstream effector of rac for fibroblast motility. Embo J, 17:1362–1370.
Fujiwara, H., Gu, J., and Sekiguchi, K., 2004, Rac regulates integrin-mediated endothelial cell adhesion and migration on laminin-8. Exp Cell Res, 292:67–77.
Ridley, A. J., 2001, Rho GTPases and cell migration. J Cell Sci, 114:2713–2722.
Lauffenburger, D. A., and Horwitz, A. F., 1996, Cell migration: a physically integrated molecular process. Cell, 84:359–369.
Wehrle-Haller, B., and Imhof, B., 2002, The inner lives of focal adhesions. Trends Cell Biol, 12:382–389.
Schlaepfer, D. D., and Hunter, T., 1996, Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases. Mol Cell Biol, 16:5623–5633.
Schaller, M. D., 2001, Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta, 1540:1–21.
Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., and Schlaepfer, D. D., 2000, FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2:249–256.
Sieg, D. J., Hauck, C. R., and Schlaepfer, D. D., 1999, Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci, 112 (Pt 16):2677–2691.
Frisch, S. M., and Francis, H., 1994, Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol, 124:619–626.
Horiguchi, A., Oya, M., Uchida, A., Marumo, K., and Murai, M., 2003, Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol, 169:710–713.
Itoh, N., Semba, S., Ito, M., Takeda, H., Kawata, S., and Yamakawa, M., 2002, Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer, 94:3127–3134.
Shindoh, M., Adachi, M., Higashino, F., Yasuda, M., Hida, K., Nishioka, T., Ono, M., Takayama, S., Reed, J. C., Imai, K., Totsuka, Y., and Kohgo, T., 2000, BAG-1 expression correlates highly with the malignant potential in early lesions (T1 and T2) of oral squamous cell carcinoma. Oral Oncol, 36:444–449.
Sun, H. Q., Yamamoto, M., Mejillano, M., and Yin, H. L., 1999, Gelsolin, a multifunctional actin regulatory protein. J Biol Chem, 274:33179–33182.
Chou, J., Stolz, D. B., Burke, N. A., Watkins, S. C., and Wells, A., 2002, Distribution of gelsolin and phosphoinositol 4,5-bisphosphate in lamellipodia during EGF-induced motility. Int J Biochem Cell Biol, 34:776–790.
Sakisaka, T., Itoh, T., Miura, K., and Takenawa, T., 1997, Phosphatidylinositol 4,5-bisphosphate phosphatase regulates the rearrangement of actin filaments. Mol Cell Biol, 17:3841–3849.
Mooseker, M. S., Coleman, T. R., and Conzelman, K. A., 1986, Calcium and the regulation of cytoskeletal assembly, structure and contractility. Ciba Found Symp, 122:232–249.
Rodland, K. D., Wersto, R. P., Hobson, S., and Kohn, E. C., 1997, Thapsigargin-induced gene expression in nonexcitable cells is dependent on calcium influx. Mol Endocrinol, 11:281–291.
Gliki, G., Wheeler-Jones, C., and Zachary, I., 2002, Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis. Cell Biol Int, 26:751–759.
Amin, A. R., Ichigotani, Y., Oo, M. L., Biswas, M. H., Yuan, H., Huang, P., Mon, N. N., and Hamaguchi, M., 2003, The PLC-PKC cascade is required for IL-1beta-dependent Erk and Akt activation: their role in proliferation. Int J Oncol, 23:1727–1731.
Legg, J. W., Lewis, C. A., Parsons, M., Ng, T., and Isacke, C. M., 2002, A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol, 4:399–407.
Ng, T., Parsons, M., Hughes, W. E., Monypenny, J., Zicha, D., Gautreau, A., Arpin, M., Gschmeissner, S., Verveer, P. J., Bastiaens, P. I., and Parker, P. J., 2001, Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility. Embo J, 20:2723–2741.
Zhang, M. I. and O'Neil, R. G., 2001, Kinetics of activation of a PKC-regulated epithelial calcium channel. Cell Calcium, 29:263–275.
Deucher, A., Efimova, T., and Eckert, R. L., 2002, Calcium-dependent involucrin expression is inversely regulated by protein kinase C (PKC) alpha and PKCdelta. J Biol Chem, 277:17032–17040.
Kamat, A., and Carpenter, G., 1997, Phospholipase C-gamma1: regulation of enzyme function and role in growth factor-dependent signal transduction. Cytokine Growth Factor Rev, 8:109–117.
Chen, W. T., 1981, Mechanism of retraction of the trailing edge during fibroblast movement. J Cell Biol, 90:187–200.
Giannone, G., Ronde, P., Gaire, M., Haiech, J., and Takeda, K., 2002, Calcium oscillations trigger focal adhesion disassembly in human U87 astrocytoma cells. J Biol Chem, 277:26364–26371.
Regen, C. M., and Horwitz, A. F., 1992, Dynamics of beta 1 integrin-mediated adhesive contacts in motile fibroblasts. J Cell Biol, 119:1347–1359.
Glading, A., Bodnar, R. J., Reynolds, I. J., Shiraha, H., Satish, L., Potter, D. A., Blair, H. C., and Wells, A., 2004, Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol Cell Biol, 24:2499–2512.
Carragher, N. O., Fincham, V. J., Riley, D., and Frame, M. C., 2001, Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases. J Biol Chem, 276:4270–4275.
Xie, H., Pallero, M. A., Gupta, K., Chang, P., Ware, M. F., Witke, W., Kwiatkowski, D. J., Lauffenburger, D. A., Murphy-Ullrich, J. E., and Wells, A., 1998, EGF receptor regulation of cell motility: EGF induces disassembly of focal adhesions independently of the motility-associated PLCgamma signaling pathway. J Cell Sci, 111 (Pt 5):615–624.
Valentinis, B., Morrione, A., Peruzzi, F., Prisco, M., Reiss, K., and Baserga, R., 1999, Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene, 18:1827–1836.
He, Z., Ismail, A., Kriazhev, L., Sadvakassova, G., and Bateman, A., 2002, Progranulin (PC-cell-derived growth factor/acrogranin) regulates invasion and cell survival. Cancer Res, 62:5590–5596.
Liu, X. W., Bernardo, M. M., Fridman, R., and Kim, H. R., 2003, Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem, 278:40364–40372.
Mills, G. B., and Moolenaar, W. H., 2003, The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer, 3:582–591.
Zhang, X., Chattopadhyay, A., Ji, Q. S., Owen, J. D., Ruest, P. J., Carpenter, G., and Hanks, S. K., 1999, Focal adhesion kinase promotes phospholipase C-gamma1 activity. Proc Natl Acad Sci USA, 96:9021–9026.
Tamura, M., Gu, J., Danen, E. H., Takino, T., Miyamoto, S., and Yamada, K. M., 1999, PTEN interactions with focal adhesion kinase and suppression of the extracellular matrix-dependent phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem, 274:20693–20703.
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R., 1997, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 275:1943–1947.
Tanaka, M., and Grossman, H. B., 2003, In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther, 10:1636–1642.
Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., Zinner, R., Hung, M. C., Steck, P., Siminovitch, K., and Mills, G. B., 1999, The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 18:7034–7045.
Krymskaya, V. P., Hoffman, R., Eszterhas, A., Kane, S., Ciocca, V., and Panettieri, R. A., Jr., 1999, EGF activates ErbB-2 and stimulates phosphatidylinositol 3-kinase in human airway smooth muscle cells. Am J Physiol, 276:L246–255.
Marmor, M. D., Skaria, K. B., and Yarden, Y., 2004, Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys, 58:903–913.
Ivaska, J., and Heino, J., 2000, Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell Mol Life Sci, 57:16–24.
Ridley, A.J., Schwartz, M.A., Burridge, K., Firtel, R. A., Ginsberg, M. H., Borisy, G., Parsons, J. T., and Horwitz, A. R., 2003, Cell migration: integrating signals from front to back. Science, 302:1704–1709.
Wary, K.K., Mainiero, F., Isakoff, S.J., Marcantonio, E.E., and Giancotti, F.G., 1996, The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. Cell, 87:733–743.
Lollo, B.A., Chan, K.W., Hanson, E.M., Moy, V.T., and Brian, A.A., 1993, Direct evidence for two affinity states for lymphocyte function-associated antigen 1 on activated T cells. J Biol Chem, 268:21693–21700.
Kim, S., Bell, K., Mousa, S. A., and Varner, J. A., 2000, Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol, 156:1345–1362.
Jin, H., and Varner, J., 2004, Integrins: roles in cancer development and as treatment targets. Br J Cancer, 90: 61–565.
Sawyer, T.K., 2004, Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. Expert Opin Investig Drugs, 13:1–19.
Stetler-Stevenson, W.G., 1999, Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest, 103:1237–1241.
Stetler-Stevenson, W.G. and Yu, A.E., 2001, Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol, 11:143–152.
Johansson, N., Ahonen, M., and Kahari, V. M., 2000, Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci, 57:5–15.
Pendas, A. M., Knauper, V., Puente, X. S., Llano, E., Mattei, M. G., Apte, S., Murphy, G., and Lopez-Otin, C., 1997, Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution. J Biol Chem, 272:4281–4286.
Lynch, C. C. and Matrisian, L. M., 2002, Matrix metalloproteinases in tumor-host cell communication. Differentiation, 70:561–573.
Brown, M. R., Blanchette, J. O., and Kohn, E. C., 2000, Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol, 14:901–918.
Kerkela, E. and Saarialho-Kere, U., 2003, Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol, 12:109–125.
Fingleton, B., 2003, Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets, 7:385–397.
Freije, J. M., Balbin, M., Pendas, A. M., Sanchez, L. M., Puente, X. S., and Lopez-Otin, C., 2003, Matrix metalloproteinases and tumor progression. Adv Exp Med Biol, 532:91–107.
Burridge, K. and Wennerberg, K., 2004, Rho and Rac take center stage. Cell, 116:167–179.
Karnoub, A. E., Symons, M., Campbell, S. L., and Der, C. J., 2004, Molecular Basis for Rho GTPase Signaling Specificity. Breast Cancer Res Treat, 84:61–71.
Li, Z., Hannigan, M., Mo, Z., Liu, B., Lu, W., Wu, Y., Smrcka, A. V., Wu, G., Li, L., Liu, M., Huang, C. K., and Wu, D., 2003, Directional sensing requires G beta gamma-mediated PAK1 and PIX alpha-dependent activation of Cdc42. Cell, 114:215–227.
Wolf, K., Mazo, I., Leung, H., Engelke, K., von Andrian, U. H., Deryugina, E. I., Strongin, A. Y., Brocker, E. B., and Friedl, P., 2003, Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol, 160:267–277.
Barnes, C. J., Bagheri-Yarmand, R., Mandal, M., Yang, Z., Clayman, G. L., Hong, W. K., and Kumar, R., 2003, Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther, 2:345–351.
Kelly, K., and Averbuch, S., 2004, Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol, 31:93–99.
Tiseo, M., Loprevite, M., and Ardizzoni, A., 2004, Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. Curr Med Chem Anti-Canc Agents, 4:139–148.
Warburton, C., Dragowska, W.H., Gelmon, K., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A.E., and Bally, M.B., 2004, Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. Clin Cancer Res, 10:2512–2524.
Zhou, H., Kim, Y. S., Peletier, A., McCall, W., Earp, H. S., and Sartor, C. I., 2004, Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys, 58:344–352.
Herbst, R. S., 2003, Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol, 30:34–46.
Christensen, J. G., Schreck, R. E., Chan, E., Wang, X., Yang, C., Liu, L., Cui, J., Sun, L., Wei, J., Cherrington, J. M., and Mendel, D. B., 2001, High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res, 7:4230–4238.
Kim, S. J., Uehara, H., Karashima, T., Shepherd, D. L., Killion, J. J., and Fidler, I. J., 2003, Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res, 9:1200–1210.
La Rosee, P., O'Dwyer, M. E., and Druker, B. J., 2002, Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia, 16:1213–1219.
DeMatteo, R. P., 2002, The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol, 9:831–839.
Hwang, R. F., Yokoi, K., Bucana, C. D., Tsan, R., Killion, J. J., Evans, D. B., and Fidler, I. J., 2003, Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res, 9:6534–6544.
Folkman, J., 1995, Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 333:1757–1763.
Liotta, L. A., Kleinerman, J., and Saidel, G. M., 1974, Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res, 34:997–1004.
Folkman, J., 1971, Tumor angiogenesis: therapeutic implications. N Engl J Med, 285:1182–1186.
Sivridis, E., Giatromanolaki, A., and Koukourakis, M. I., 2003, The vascular network of tumours—what is it not for? J Pathol, 201:173–180.
Sieczkiewicz, G. J., Hussain, M., and Kohn, E. C., 2002, Angiogenesis and metastasis. Cancer Treat Res, 107:353–381.
Risau, W., 1997, Mechanisms of angiogenesis. Nature, 386:671–674.
Folkman, J., Merler, E., Abernathy, C., and Williams, G., 1971, Isolation of a tumor factor responsible or angiogenesis. J Exp Med, 133:275–288.
Goto, F., Goto, K., Weindel, K., and Folkman, J., 1993, Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest, 69:508–517.
Carmeliet, P. and Jain, R. K., 2000, Angiogenesis in cancer and other diseases. Nature, 407:249–257.
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'shea, K. S., Powell-Braxton, L., Hillan, K. J., and Moore, M. W., 1996, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature, 380:439–442.
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., Mino, M., Cohen, K. S., Scadden, D. T., Hartford, A. C., Fischman, A. J., Clark, J. W., Ryan, D. P., Zhu, A. X., Blaszkowsky, L. S., Chen, H. X., Shellito, P. C., Lauwers, G. Y., and Jain, R. K., 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10:145–147.
Guidi, A. J., Abu-Jawdeh, G., Berse, B., Jackman, R. W., Tognazzi, K., Dvorak, H. F., and Brown, L. F., 1995, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst, 87:1237–1245.
Guidi, A. J., Abu-Jawdeh, G., Tognazzi, K., Dvorak, H. F., and Brown, L. F., 1996, Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer, 78: 454–460.
Hartenbach, E. M., Olson, T. A., Goswitz, J. J., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S., 1997, Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett, 121:169–175.
Price, J. T., Bonovich, M. T., and Kohn, E. C., 1997, The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol, 32:175–253.
Kumar, R., Kuniyasu, H., Bucana, C. D., Wilson, M. R., and Fidler, I. J., 1998, Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res, 10:301–311.
Ferrara, N., Gerber, H. P., and LeCouter, J., 2003, The biology of VEGF and its receptors. Nat Med, 9:669–676.
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F., 1983, Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219:983–985.
Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z., 1999, Vascular endothelial growth factor (VEGF) and its receptors. Faseb J, 13:9–22.
de Vries, C., Escobedo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T., 1992, The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255:989–991.
Terman, B. I., Dougher-Vermazen, M., Carrion, M. E., Dimitrov, D., Armellino, D. C., Gospodarowicz, D., and Bohlen, P., 1992, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun, 187:1579–1586.
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X. F., Breitman, M. L., and Schuh, A. C., 1995, Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376:62–66.
Olson, T. A., Mohanraj, D., Carson, L. F., and Ramakrishnan, S., 1994, Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res, 54: 276–280.
Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., and Ramakrishnan, S., 1997, Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 80:98–106.
Paley, P. J., Goff, B. A., Gown, A. M., Greer, B. E., and Sage, E. H., 2000, Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol, 78:336–341.
Eppenberger, U., Kueng, W., Schlaeppi, J. M., Roesel, J. L., Benz, C., Mueller, H., Matter, A., Zuber, M., Luescher, K., Litschgi, M., Schmitt, M., Foekens, J. A., and Eppenberger-Castori, S., 1998, Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol, 16:3129–3136.
Linderholm, B., Tavelin, B., Grankvist, K., and Henriksson, R., 1998, Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol, 16:3121–3128.
George, D. J., and Kaelin, W. G., Jr., 2003, The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med, 349:419–421.
Igarashi, H., Esumi, M., Ishida, H., and Okada, K., 2002, Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer, 95:47–53.
Rosen, L. S., 2002, Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am, 16:1173–1187.
Patel, N., Sun, L., Moshinsky, D., Chen, H., Leahy, K. M., Le, P., Moss, K. G., Wang, X., Rice, A., Tam, D., Laird, A. D., Yu, X., Zhang, Q., Tang, C., McMahon, G., and Howlett, A., 2003, A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J Pharmacol Exp Ther, 306 838–845.
Hotte, S. J., and Hirte, H. W., 2002, BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des, 8:2249–2253.
Giantonio, B. J., Levy, D., O'Dwyer, N. J., Catalano, P. J., and Benson, A. B., 2003, Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. In: Proc Am Soc Clin Oncol, No. 1024, Chicago, IL.
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., and Rosenberg, S. A., 2003, A randomized trail of Bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349:427–434.
Asano, M., Yukita, A., and Suzuki, H., 1999, Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor. Jpn J Cancer Res, 90:93–100.
Jayson, G., Mulater, C., Ranson, M., Zweit, J., Hasting, D., Julyan, P., Lawrance, J., McGown, A., Jackson, A., Haroon, H., Hakannson, L., Wagstaff, J., Groenewegen, G., Lehmann, F., Levitt, D., Tang, T., and Zweirzina, H., 2001, Anti-VEGF Antibody HuMV833: an EORTC Biological Treatment Development Group Phase I toxicity, pharmacokinetic, and pharmacodynamic study. In: Proc Am Soc Clin Oncol, No. 14, San Francisco, CA.
Heldin, C. H., and Westermark, B., 1999, Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev, 79:1283–1316.
Henriksen, R., Funa, K., Wilander, E., Backstrom, T., Ridderheim, M., and Oberg, K., 1993, Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res, 53:4550–4554.
Thommen, R., Humar, R., Misevic, G., Pepper, M. S., Hahn, A. W., John, M., and Battegay, E. J., 1997, PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. J Cell Biochem, 64:403–413.
Sundberg, C., Ljungstrom, M., Lindmark, G., Gerdin, B., and Rubin, K., 1993, Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. Am J Pathol, 143:1377–1388.
Wang, D., Huang, H. J., Kazlauskas, A., and Cavenee, W. K., 1999, Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res, 59:1464–1472.
Reinmuth, N., Liu, W., Jung, Y. D., Ahmad, S. A., Shaheen, R. M., Fan, F., Bucana, C. D., McMahon, G., Gallick, G. E., and Ellis, L. M., 2001, Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. Faseb J, 15:1239–1241.
Lindahl, P., Johansson, B. R., Leveen, P., and Betsholtz, C., 1997, Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science, 277:242–245.
Demetri, G. D., 2001, Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol, 28:19–26.
Greco, A., Roccato, E., Miranda, C., Cleris, L., Formelli, F., and Pierotti, M. A., 2001, Growthinhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer, 92:354–360.
Myllarniemi, M., Calderon, L., Lemstrom, K., Buchdunger, E., and Hayry, P., 1997, Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. Faseb J, 11:1119–1126.
Schmandt, R. E., Broaddus, R., Lu, K. H., Shvartsman, H., Thornton, A., Malpica, A., Sun, C., Bodurka, D. C., and Gershenson, D. M., 2003, Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 98:758–764.
Link, C.J., Jr., Kohn, E., and Reed, E., 1996, The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: epidemiologic, pathologic, and molecular aspects. Gynecol Oncol, 60:347–354.
Capdeville, R., Buchdunger, E., Zimmermann, J., and Matter, A., 2002, Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov, 1:493–502.
Dudley, A., Gilbert, R. E., Thomas, D., Cox, A., Price, J. T., Best, J., and Jenkins, A., 2003, STI-571 inhibits in vitro angiogenesis. Biochem Biophys Res Commun, 310:135–142.
Atallah, E., Talpaz, M., O'Brien, S., Rios, M. B., Guo, J. Q., Arlinghaus, R., Fernandes-Reese, S., and Kantarjian, H., 2002, Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. Cancer, 94:2996–2999.
Barbany, G., Hoglund, M., and Simonsson, B., 2002, Complete molecular remission in chronic myelogenous leukemia after imatinib therapy. N Engl J Med, 347:539–540.
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D., and Joensuu, H., 2002, Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347:472–480.
Demetri, G. D., George, S., Heinrich, M. C., Fletcher, J. A., Fletcher, C. D. M., Desai, J., Cohen, D. P., Scigalla, P., Cherrington, J., and Van Den Abbeele, A. D., 2003, Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. In: Proc Am Soc Clin Oncol No. 3273, Chicago, IL.
Raymond, E., Faivre, S., Vera, K., Delbaldo, C., Robert, C., Spatz, A., Bello, C., Brega, N., Scigalla, P., and Armand, J. P., 2003, Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. In: Proc Am Soc Clin Oncol, No. 769, Chicago, IL.
Mall, J. W., Myers, J. A., Xu, X., Saclarides, T. J., Philipp, A. W., and Pollmann, C., 2002, [Leflunomide reduces the angiogenesis score and tumor growth of subcutaneously implanted colon carcinoma cells in the mouse model]. Chirurg, 73:716–720.
Shawver, L. K., Schwartz, D. P., Mann, E., Chen, H., Tsai, J., Chu, L., Taylorson, L., Longhi, M., Meredith, S., Germain, L., Jacobs, J. S., Tang, C., Ullrich, A., Berens, M. E., Hersh, E., McMahon, G., Hirth, K. P., and Powell, T. J., 1997, Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Cancer Res, 3:1167–1177.
Ko, Y. J., Chachou, A., Small, E., Reese, D., Kabbinavar, F., Taneja, S., DePaoli, A., Hannah, A., Balk, S., and Bubley, G., 1999, Phase II study of SU101 in patients with PSA-positive prostate cancer. In: Proc Am Soc Clin Oncol, No. 1220, Atlanta, GA.
Folkman, J., Klagsbrun, M., Sasse, J., Wadzinski, M., Ingber, D., and Vlodavsky, I., 1988, A heparinbinding angiogenic protein—basic fibroblast growth factor—is stored within basement membrane. Am J Pathol, 130:393–400.
Wiesmann, C., Muller, Y. A., and de Vos, A. M., 2000, Ligand-binding sites in Ig-like domains of receptor tyrosine kinases. J Mol Med, 78:247–260.
Dono, R., Texido, G., Dussel, R., Ehmke, H., and Zeller, R., 1998, Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. Embo J, 17:4213–4225.
Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., Robbins, E. S., Shapiro, R. L., Galloway, A. C., Rifkin, D. B., and Mignatti, P., 1998, Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol, 141:1659–1673.
Brooks, P. C., Clark, R. A., and Cheresh, D. A., 1994, Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science, 264:569–571.
Klagsbrun, M., and Baird, A., 1991, A dual receptor system is required for basic fibroblast growth factor activity. Cell, 67:229–231.
Netzer, P., Domek, M., Pai, R., Halter, F., and Tarnawski, A., 2001, Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth factor. Aliment Pharmacol Ther, 15:1673–1679.
Crickard, K., Gross, J. L., Crickard, U., Yoonessi, M., Lele, S., Herblin, W. F., and Eidsvoog, K., 1994, Basic fibroblast growth factor and receptor expression in human ovarian cancer. Gynecol Oncol, 55:277–284.
Miyake, H., Hara, I., Yoshimura, K., Eto, H., Arakawa, S., Wada, S., Chihara, K., and Kamidono, S., 1996, Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res, 56:2440–2445.
Tsuboi, R., Sato, Y., and Rifkin, D. B., 1990, Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. J Cell Biol, 110:511–517.
Miyake, H., Yoshimura, K., Hara, I., Eto, H., Arakawa, S., and Kamidono, S., 1997, Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol, 157:2351–2355.
Sliutz, G., Tempfer, C., Obermair, A., Dadak, C., and Kainz, C., 1995, Serum evaluation of basic FGF in breast cancer patients. Anticancer Res, 15:2675–2677.
Dosquet, C., Coudert, M. C., Lepage, E., Cabane, J., and Richard, F., 1997, Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res, 3:2451–2458.
Davidson, B., Goldberg, I., Kopolovic, J., Gotlieb, W. H., Givant-Horwitz, V., Nesland, J. M., Berner, A., Ben-Baruch, G., Bryne, M., and Reich, R., 2000, Expression of angiogenesis-related genes in ovarian carcinoma—a clinicopathologic study. Clin Exp Metastasis, 18:501–507.
Prindull, G., and Zipori, D., 2004, Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood, 103:2892–2899.
Bush, K. T., Sakurai, H., Steer, D. L., Leonard, M. O., Sampogna, R. V., Meyer, T. N., Schwesinger, C., Qiao, J., and Nigam, S. K., 2004, TGF-beta superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol, 266:285–298.
Klein, C. A., Blankenstein, T. J., Schmidt-Kittler, O., Petronio, M., Polzer, B., Stoecklein, N. H., and Riethmuller, G., 2002, Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet, 360:683–689.
Zoltan-Jones, A., Huang, L., Ghatak, S., and Toole, B. P., 2003, Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells. J Biol Chem, 278:45801–45810.
Tanaka, K., Hiraiwa, N., Hashimoto, H., Yamazaki, Y., and Kusakabe, M., 2004, Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer, 108:31–40.
Tlsty, T. D., and Hein, P. W., 2001, Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev, 11:54–59.
Piek, E., Moustakas, A., Kurisaki, A., Heldin, C. H., and ten Dijke, P., 1999, TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci, 112 (Pt 24):4557–4568.
Jechlinger, M., Grunert, S., Tamir, I. H., Janda, E., Ludemann, S., Waerner, T., Seither, P., Weith, A., Beug, H., and Kraut, N., 2003, Expression profiling of epithelial plasticity in tumor progression. Oncogene, 22:7155–7169.
Jiang, Y., Henderson, D., Blackstad, M., Chen, A., Miller, R. F., and Verfaillie, C. M., 2003, Neuroectodermal differentiation from mouse multipotent adult progenitor cells. Proc Natl Acad Sci USA, 100Suppl 1:11854–11860.
Wagers, A. J., Sherwood, R. I., Christensen, J. L., and Weissman, I. L., 2002, Little evidence for developmental plasticity of adult hematopoietic stem cells. Science, 297:2256–2259.
Toma, J. G., Akhavan, M., Fernandes, K. J., Barnabe-Heider, F., Sadikot, A., Kaplan, D. R., and Miller, F. D., 2001, Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol, 3:778–784.
Krause, D. S., Theise, N. D., Collector, M. I., Henegariu, O., Hwang, S., Gardner, R., Neutzel, S., and Sharkis, S. J., 2001, Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell, 105:369–377.
Liang, L., and Bickenbach, J. R., 2002, Somatic epidermal stem cells can produce multiple cell lineages during development. Stem Cells, 20:21–31.
Cao, B., Zheng, B., Jankowski, R. J., Kimura, S., Ikezawa, M., Deasy, B., Cummins, J., Epperly, M., Qu-Petersen, Z., and Huard, J., 2003, Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential. Nat Cell Biol, 5:640–646.
Vassilopoulos, G., Wang, P. R., and Russell, D. W., 2003, Transplanted bone marrow regenerates liver by cell fusion. Nature, 422:901–904.
McKinney-Freeman, S. L., Jackson, K. A., Camargo, F. D., Ferrari, G., Mavilio, F., and Goodell, M. A., 2002, Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci U S A, 99:1341–1346.
Gilchrist, A. J., Meuser, R., Turchinsky, J., Shaw, A. R., Pasdar, M., and Dixon, W. T., 2002, Cell adhesion-mediated transformation of a human SCLC cell line is associated with the development of a normal phenotype. Exp Cell Res, 276:63–78.
Liotta, L. A., Kohn, E. C., and Petricoin, E. F., 2001, Clinical proteomics: personalized molecular medicine. Jama, 286:2211–2214.
Nishizuka, S., Chen, S. T., Gwadry, F. G., Alexander, J., Major, S. M., Scherf, U., Reinhold, W. C., Waltham, M., Charboneau, L., Young, L., Bussey, K. J., Kim, S., Lababidi, S., Lee, J. K., Pittaluga, S., Scudiero, D. A., Sausville, E. A., Munson, P. J., Petricoin, E. F., 3rd, Liotta, L. A., Hewitt, S. M., Raffeld, M., and Weinstein, J. N., 2003, Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res, 63:5243–5250.
Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., and Petricoin, E. F., 3rd, 2002, Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics, 2:76–84.
Stevens, E. V., Liotta, L. A., and Kohn, E. C., 2003, Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int J Gynecol Cancer, 13Suppl 2:133–139.
Mehta, A., Lowenthal, M., Johann, D., Rajapakse, V., Fusaro, V., Hoatson, S., Asmussen, H., Roberts, J., Butler, C., Pappas, R., Ross, S., Fishman, D., Petricoin III, E., and Liotta, L. A., 2004, Carrier albumin's binders in serum (CABs): Detecting ovarian cancer. In: American Association of Cancer Research, No. 4774, Orlando, FL.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer
About this chapter
Cite this chapter
Kassis, J., Alejandro, E., Virador, V., Kohn, E.C. (2005). Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. In: Meadows, G.G. (eds) Integration/Interaction of Oncologic Growth. Cancer Growth and Progression, vol 15. Springer, Dordrecht. https://doi.org/10.1007/1-4020-3414-8_20
Download citation
DOI: https://doi.org/10.1007/1-4020-3414-8_20
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-3413-8
Online ISBN: 978-1-4020-3414-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)